RxDoctor Payments Data

Steven Rider, MD

Neurology · Knoxville, TNNPI 1730159534

Payments from drug & device makers

$11,370in general payments, 2019–2025

Across 594 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • AbbVie$1K
  • AstraZeneca$631
  • CSL Behring$517
  • Novartis$457
  • Neurelis, Inc.$425
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$11,322100%
  • Education$480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.63$1,275
AbbVie(2 entities)77$1,168
AstraZeneca(2 entities)35$631
CSL Behring20$517
Novartis25$457
Neurelis, Inc.20$425
Biogen20$407
Sanofi19$403
Amgen(2 entities)14$377
Supernus Pharmaceuticals, Inc.31$347
Eisai Inc.14$256
EMD Serono, Inc.12$236
Greenwich Biosciences, Inc.5$215
Lundbeck LLC11$201
Biohaven Pharmaceuticals, Inc.9$198
Bristol Myers Squibb10$193
Takeda Pharmaceuticals U.S.A., Inc.6$188
Biohaven Pharmaceutical Holding Company Ltd.9$179
Genentech USA, Inc.7$175
Akcea Therapeutics, Inc.2$170
Adamas Pharmaceuticals, Inc.8$169
Pfizer9$169
Alnylam Pharmaceuticals Inc.7$165
Upsher-smith Laboratories LLC10$159
Acadia Pharmaceuticals Inc6$124
TG Therapeutics, Inc.5$122
Jazz Pharmaceuticals Inc.4$111
Arbor Pharmaceuticals, Inc.6$101
Grifols USA, LLC5$99
Avanir Pharmaceuticals, Inc.7$98
Sunovion Pharmaceuticals Inc.9$97
E.r. Squibb & Sons, L.L.C.5$93
Lilly USA, LLC6$92
Hospira, Inc.4$89
Sumitomo Pharma America, Inc.8$86
Banner Life Sciences, LLC4$85
Neurocrine Biosciences, Inc.4$85
Argenx US, Inc.4$84
Kyowa Kirin, Inc.5$84
Merz Pharmaceuticals, LLC3$82
Catalyst Pharmaceuticals, Inc.5$76
Mallinckrodt Hospital Products Inc.3$74
Johnson & Johnson3$71
Tanabe Pharma America, Inc.4$64
Octapharma USA, Inc.3$61
Teva Pharmaceuticals USA, Inc.4$55
Amneal Pharmaceuticals LLC3$46
Livanova USA, Inc.3$44
GE HealthCare2$44
Otsuka America Pharmaceutical, Inc.2$38
Merz North America, Inc.2$37
Azurity Pharmaceuticals, Inc.2$35
SK Life Science, Inc.2$34
Impel Pharmaceuticals Inc.2$33
Neuropace, Inc.1$33
Cycle Pharmaceuticals Inc2$29
ANI Pharmaceuticals, Inc.1$26
Assertio Therapeutics, Inc.2$26
Kedrion Biopharma, Inc.1$25
Impel Pharmaceuticals LLC1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,370 in reported general payments places this provider in the 60th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$41,236
Medicare patients
418
Services billed
479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SabrilVigabatrin12$411,795
EpidiolexCannabidiol (Cbd)101$368,922
FinteplaFenfluramine Hcl12$240,764
Vigabatrin12$197,373
AptiomEslicarbazepine Acetate91$180,949
Nurtec OdtRimegepant Sulfate104$135,612
BriviactBrivaracetam81$134,611
OnfiClobazam32$115,196
KeppraLevetiracetam37$103,259
XcopriCenobamate53$73,661
VimpatLacosamide62$72,043
Emgality PenGalcanezumab-Gnlm91$70,855
FycompaPerampanel57$66,131
Oxtellar XrOxcarbazepine23$62,889
UbrelvyUbrogepant47$60,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lundbeck LLCSabril, Onfi$201$526,99144 claims
UCB, Inc.Fintepla, Briviact, Vimpat, Nayzilam$1,275$475,816190 claims
Sunovion Pharmaceuticals Inc.Aptiom$97$180,94991 claims
PfizerNurtec Odt, Dilantin$169$148,289206 claims
Eisai Inc.Fycompa, Banzel$256$113,03469 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr, Trokendi Xr$347$88,23242 claims
AbbVieUbrelvy, Qulipta$1,168$74,17660 claims
SK Life Science, Inc.Xcopri$34$73,66153 claims
Arbor Pharmaceuticals, Inc.Horizant$101$11,20712 claims
Lilly USA, LLCReyvow$92$8,68412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 361 neurology providers in Tennessee.

Other neurology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →